Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Claus Thestrup

CEO, Sweden

Claus Thestrup portrait

Coverage

BoMillFlerieNeoDynamicsPharma Equity GroupExpreS2ion Biotech HoldingQlife Holding

Latest content

ShowingAll content types

Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point

Research 10.09.2025 klo 09.31 by Claus Thestrup, Philip Coombes
Pharma Equity Group

Bioporto (One-pager): Strong Partnerships, Clear Milestones, Global Potential

Research 03.09.2025 klo 09.48 by Philip Coombes, Claus Thestrup
BioPorto

Ascelia Pharma: Video presentation of the Half-Year Report 2025

Analyst Comment 22.08.2025 klo 12.48 by Claus Thestrup
Ascelia Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Ascelia Pharma (One-pager): Bridging the gap between phase III success and FDA approval

Research 19.08.2025 klo 15.47 by Claus Thestrup, Philip Coombes
Ascelia Pharma

Ascelia Pharma: Ahead of the company's Q2 and Half-Year Report 2025

Analyst Comment 09.07.2025 klo 08.50 by Claus Thestrup
Ascelia Pharma

ExpreS2ion Biotech (One-pager): Pipeline focus on HER2+ breast cancer therapy

Research 10.06.2025 klo 09.57 by Philip Coombes, Claus Thestrup, Michael Friis
ExpreS2ion Biotech Holding

Ascelia Pharma - Recording of Q1-2025 presentation

Analyst Comment 20.05.2025 klo 09.02 by Claus Thestrup
Ascelia Pharma

Ascelia Pharma: Q1 report with positive Outcome of Orviglance FDA Meeting

Analyst Comment 16.05.2025 klo 10.11 by Claus Thestrup
Ascelia Pharma

Gubra: Trading statement Q1-2025

Analyst Comment 09.05.2025 klo 09.20 by Claus Thestrup
Gubra

Curasight (One-pager): Funding of pipeline

Research 07.05.2025 klo 09.02 by Philip Coombes, Claus Thestrup
Curasight
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.